Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 February 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 February 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 February 2026, reflecting a reassessment of the stock’s outlook. However, the analysis below is based on the company’s current fundamentals, returns, and financial metrics as of 08 June 2026, providing investors with an up-to-date view of the stock’s position.

Dishman Carbogen Amcis Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent downgrade to a Strong Sell rating by MarketsMOJO, the stock exhibits a complex interplay of technical indicators that suggest cautious investor sentiment amid mixed signals.

Dishman Carbogen Amcis Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest day gain of 1.18%, the stock’s broader technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, reflecting cautious investor sentiment amid ongoing market volatility.

Dishman Carbogen Amcis Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key indicators such as MACD, RSI, and moving averages. Despite a recent downgrade to a Strong Sell rating, the stock’s technical profile reveals nuanced market dynamics that investors should carefully consider.

Dishman Carbogen Amcis Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent 2.17% gain in daily price, the company’s overall technical and fundamental outlook remains cautious, as indicated by its downgrade to a Strong Sell rating by MarketsMOJO on 12 January 2026.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 04 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 May 2026, providing investors with the latest insights into its performance and outlook.

Dishman Carbogen Amcis Ltd experienced a notable intraday decline on 22 May 2026, with the stock touching a low of Rs 197.05, down 7.44% from its previous close. This sharp fall contrasts with the broader market’s positive momentum, as the Sensex advanced by 0.57% during the session.

Dishman Carbogen Amcis Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in price momentum, reflected in a 12.01% surge in its share price on 21 May 2026. Despite this intraday strength, technical indicators present a complex picture with mixed signals across weekly and monthly timeframes, prompting a reassessment of the stock’s near-term outlook.

Dishman Carbogen Amcis Ltd., a contract research and manufacturing services (CRAMS) provider with operations spanning Switzerland, the UK, Europe, and China, reported its Q4 FY26 results that painted a concerning picture of profitability challenges despite robust revenue momentum. The company posted a net profit of ₹21.74 crores for the quarter ended March 2026, marking a dramatic 49.55% decline year-on-year from ₹43.09 crores in Q4 FY25. The stock surged 12.01% to ₹211.20 following the announcement, though it remains 34.24% below its 52-week high of ₹321.15.

The Sensex declined by 0.48% on 20 May 2026, while Dishman Carbogen Amcis Ltd surged 7.74%, marking a remarkable 6.73-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector. This sharp single-session gain rewrites the short-term narrative for the stock, which has been on a two-day winning streak.

The Sensex advanced 0.42% on 15 May 2026, yet Dishman Carbogen Amcis Ltd outpaced the broader market with an 8.46% gain, touching an intraday high of Rs 194. This 8.41 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a market-wide lift.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 Feb 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 14 May 2026, providing investors with the latest perspective on the company’s position.

Dishman Carbogen Amcis Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 04 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 May 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.